Stevenage Bioscience Catalyst

Over 200 life science innovators, companies and their supporters came to celebrate success at London’s No. 11 Cavendish Square. Eight winners were announced from a series of shortlisted entrants across categories for Best Performing: Primary R&D Company; Investor; Provider; Technology Transfer Office; Professional Services Company; Facilities Provider; Non-Profit Research Organisation; Non-Profit Life Science Innovation Enablers.

The initiative will provide a further four years of funding for the Advanced Therapy Treatment Centre Network (ATTC Network). The funding will come from NIHR, Innovate UK will provide oversight of the funds and CGT Catapult provide co-ordination of the network.

Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister launch Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC). Shadow Ministers take part in roundtable discussion with key industry figures including AstraZeneca, GSK, BioIndustry Association (BIA) and Stevenage Bioscience Catalyst and its high growth companies to hear at first hand the opportunities and challenges facing the sector and the vibrant strength of the UK’s life science ecosystem.

This January, Stevenage Bioscience Catalyst is launching their accelerator programme for a third year! The Catalyser programme is designed specifically for start-ups specialising in human health innovation who want to refine their commercialisation strategy. Using a unique framework called Triple Chasm, the programme helps businesses understand how to deliver their science to market. Feedback from cohort members in 2023 include: “The expert guidance and practical insights provided were invaluable.

Published on 16th November 2023 by Cell and Gene Therapy Catapult The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, today publishes its Annual Review 2023, highlighting the significant opportunity advanced therapies represent to industry, the UK economy, and patients in need.

New tag technology is self-cleaving and traceless, helping drug developers and manufacturers obtain pure proteins without remaining tag residues. New affinity chromatography resin and tag combination is applicable from early research through to bioprocessing. Cytiva, a global leader in life sciences, introduces the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant protein purification.

TauC3 Biologics Ltd, focused on therapies for the treatment of neurodegenerative diseases, has chosen Stevenage Bioscience Catalyst as its premier location to accelerate its science by acquiring 1,046 sq ft of lab space. TauC3 Biologics is focused on the development of innovative high precision immunotherapy for the treatment of the devastating neurodegenerative diseases known as tauopathies, particularly tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP).

Platform products Intellectual Property protection extended to 2043 10th October 2023 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has filed a global Patent Co-Operation Treaty (PCT) for the method of using radiotherapy parameters for clinical studies on radiation induced oral mucositis, supported by leading IP agency Gill Jennings & Every LLP.

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.

RS&RS Scientific and Native Labs are the newest arrivals to check in to Stevenage Bioscience Catalyst’s Lab Hotel to accelerate their R&D in a shared, collaborative space designed to help fledging therapeutics companies grow. RS&RS Scientific is a pioneering research organisation dedicated to advancing healthcare through innovative solutions.